Decitabine: a historical review of the development of an epigenetic drug
| Autor: | Wendy van Overveld, Dick de Vos |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Oncology
Drug medicine.medical_specialty Transplantation Conditioning media_common.quotation_subject Thalassemia Decitabine Hypomethylation Anemia Sickle Cell History 21st Century Epigenesis Genetic sickle cell AML hemic and lymphatic diseases Internal medicine MDS medicine Humans Epigenetics DNA Modification Methylases Epigenesis media_common Hematology business.industry CML stem cell General Medicine History 20th Century medicine.disease Sickle cell anemia Drug Design Myelodysplastic Syndromes Immunology Azacitidine Original Article Stem cell business medicine.drug |
| Zdroj: | Annals of Hematology |
| ISSN: | 1432-0584 0939-5555 |
| DOI: | 10.1007/s00277-005-0008-x |
| Popis: | The development of decitabine from its synthesis in 1964 to the submission of a registration file has been described. Although the unique DNA-demethylating capacity of decitabine is known for a long time, its application is under continuing investigation. The use of decitabine in MDS, AML, CML, stem cell transplant, sickle cell anemia and thalassemia looks promising. The epigenetic dose seems lower than the cytotoxic dose. Whereas most drugs have matured after 40 years, decitabine is only at the beginning of a new development phase in epigenesis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink